Company: Incyte
Posted by JakafiWatcher_INC · March 22, 2026
Tags: pipeline, compensation, rumors
Incyte leadership keeps saying Jakafi is protected and the data package is defensible against biosimilars.
What they don't say is that payer contracts are already shifting in anticipation.
I had two accounts get converted to biosimilar-preferred before any biosimilar even launched in my indication.
Payers are moving preemptively.
If your Incyte comp is heavily weighted toward Jakafi volume you should be having a serious conversation with your DM about what 2027 looks like.
I'm not saying jump ship but I'm saying don't wait until it's obvious.
The signs are there now.
17 upvotes · 0 comments